Tema Etfs LLC Invests $1.7M in Halozyme Therapeutics

The investment firm purchased over 25,000 shares of the biopharmaceutical company in Q4 2025.

Apr. 3, 2026 at 9:54am

Got story updates? Submit your updates here. ›

A highly detailed, black-and-white close-up image of complex, industrial-looking banking machinery and gears, conceptually representing the complex financial infrastructure behind biotech investments.An extreme close-up of the inner workings of the financial system highlights the growing investment in innovative biotech companies like Halozyme Therapeutics.San Diego Today

Tema Etfs LLC, an investment firm, purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the fourth quarter of 2025. The fund bought 25,256 shares of the biopharmaceutical company's stock, valued at approximately $1.7 million.

Why it matters

Halozyme Therapeutics is a leading biopharmaceutical company focused on developing novel drug delivery technologies. This investment by Tema Etfs LLC signals confidence in Halozyme's growth potential and the broader trends in the biotech industry.

The details

According to a recent SEC filing, Tema Etfs LLC acquired the new position in Halozyme Therapeutics during the fourth quarter of 2025. The investment firm purchased 25,256 shares of the company's stock, valued at around $1.7 million. This move comes as Halozyme continues to develop its proprietary ENHANZE® technology, which enables subcutaneous administration of biologic therapies.

  • Tema Etfs LLC purchased the Halozyme Therapeutics shares in the fourth quarter of 2025.

The players

Tema Etfs LLC

An investment firm that purchased a new position in shares of Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc.

A biopharmaceutical company that specializes in the development and commercialization of novel drug-delivery technologies, including its flagship ENHANZE® platform.

Got photos? Submit your photos here. ›

The takeaway

This investment by Tema Etfs LLC underscores the growing interest in Halozyme Therapeutics and its innovative drug delivery technologies. As the biotech industry continues to evolve, Halozyme's focus on improving patient access and convenience through subcutaneous administration could position the company for further growth and investor attention.